Canaccord Genuity Initiates Coverage On CervoMed With Buy Rating, Announces Price Target of $50
Canaccord Genuity Initiates Coverage On CervoMed With Buy Rating, Announces Price Target of $50
Canaccord Genuity以買入評級啓動對CervoMed的報道，宣佈目標股價爲50美元
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and announces Price Target of $50.
Canaccord Genuity分析師蘇曼特·庫爾卡尼以買入評級開始對CervoMed（納斯達克股票代碼：CRVO）進行報道，並宣佈目標股價爲50美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。